Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: pramlintide acetate

« Back to Dashboard

Summary for Generic Name: pramlintide acetate

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers: see list1
Therapeutic Class:Blood Glucose Regulators

Pharmacology for Ingredient: pramlintide acetate

Drug ClassAmylin Analog
Mechanism of ActionAmylin Agonists

Clinical Trials for: pramlintide acetate

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
Status: Completed Condition: Overweight; Obesity

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
Status: Completed Condition: Type 1 Diabetes Mellitus

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
Status: Completed Condition: Overweight; Obesity

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
Status: Completed Condition: IDDM

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Status: Completed Condition: Obesity

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
Status: Active, not recruiting Condition: Type 1 Diabetes

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes
Status: Withdrawn Condition: Type 1 Diabetes

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes
Status: Recruiting Condition: Type 2 Diabetes

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
Status: Completed Condition: Type 1 Diabetes

Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide
Status: Completed Condition: Type 1 Diabetes

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXYes6,114,304<disabled><disabled>
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Mar 16, 2005DISCNNo6,608,029<disabled><disabled>
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXYes6,608,029<disabled><disabled>
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXYes5,814,600<disabled><disabled>
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXYes5,686,411<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc